Trial Profile
Difference in Omalizumab Treatment Response in Patients With Chronic Autoimmune Urticaria vs Chronic Spontaneous Urticaria
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Mar 2018
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 26 Mar 2018 New trial record
- 05 Mar 2018 Results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology